The relationship between the expression of FOXA1 and GATA3 and the efficacy of neoadjuvant endocrine therapy.

about

The relationship between the expression of FOXA1 and GATA3 and the efficacy of neoadjuvant endocrine therapy.

Item

http://www.wikidata.org/entity/Q51606753

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

The relationship between the e ...... neoadjuvant endocrine therapy.

@en

The relationship between the e ...... neoadjuvant endocrine therapy.

@nl

type

Item

label

The relationship between the e ...... neoadjuvant endocrine therapy.

@en

The relationship between the e ...... neoadjuvant endocrine therapy.

@nl

prefLabel

The relationship between the e ...... neoadjuvant endocrine therapy.

@en

The relationship between the e ...... neoadjuvant endocrine therapy.

@nl

P1476

The relationship between the e ...... neoadjuvant endocrine therapy

@en

P2093

Eriko Tokunaga

http://www.w3.org/2001/XMLSchema#string

Kenichi Taguchi

http://www.w3.org/2001/XMLSchema#string

Kimihiro Tanaka

http://www.w3.org/2001/XMLSchema#string

Nami Yamashita

http://www.w3.org/2001/XMLSchema#string

Shinji Ohno

http://www.w3.org/2001/XMLSchema#string

Shinji Okano

http://www.w3.org/2001/XMLSchema#string

Yasuyo Ohi

http://www.w3.org/2001/XMLSchema#string

Yoshihiko Maehara

http://www.w3.org/2001/XMLSchema#string

Yoshinao Oda

http://www.w3.org/2001/XMLSchema#string

P2860

FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis

Pioneer transcription factors: establishing competence for gene expression

GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Molecular portraits of human breast tumours

Repeated observation of breast tumor subtypes in independent gene expression data sets

Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.

FOXA1 is a key determinant of estrogen receptor function and endocrine response

P2888

s12282-016-0714-3

P304

384-392

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12282-016-0714-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yasuaki Sagara

P577

2016-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27473079

http://www.w3.org/2001/XMLSchema#string